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Abstract
Background: In the presence of comorbidities the effectiveness of many cardioprotective strategies is blunted. The goal of
this study was to assess in a hypertensive rat model if the early reperfusion with anti-hypertensive and pro-angiogenic
Chromogranin A-derived peptide, Catestatin (CST:hCgA352–372; CST-Post), protects the heart via Reperfusion-Injury-Salvage-
Kinases (RISK)-pathway activation, limiting infarct-size and apoptosis, and promoting angiogenetic factors (e.g., hypoxia
inducible factor, HIF-1a, and endothelial nitric oxide synthase, eNOS, expression).
Methods and Results: The effects of CST-Post on infarct-size, apoptosis and pro-angiogenetic factors were studied in
isolated hearts of spontaneously hypertensive rats (SHR), which underwent the following protocols: (a) 30-min ischemia and
120-min reperfusion (I/R); (b) 30-min ischemia and 20-min reperfusion (I/R-short), both with and without CST-Post (75 nM
for 20-min at the beginning of reperfusion). In unprotected Wistar-Kyoto hearts, used as normal counterpart, infarct-size
resulted smaller than in SHR. CST-Post reduced significantly infarct-size and improved post-ischemic cardiac function in
both strains. After 20-min reperfusion, CST-Post induced S-nitrosylation of calcium channels and phosphorylation of RISK-
pathway in WKY and SHR hearts. Yet specific inhibitors of the RISK pathway blocked the CST-Post protective effects against
infarct in the 120-min reperfusion groups. Moreover, apoptosis (evaluated by TUNEL, ARC and cleaved caspase) was
reduced by CST-Post. Importantly, CST-Post increased expression of pro-angiogenetic factors (i.e., HIF-1a and eNOS
expression) after two-hour reperfusion.
Conclusions: CST-Post limits reperfusion damages and reverses the hypertension-induced increase of I/R susceptibility.
Moreover, CST-Post triggers antiapoptotic and pro-angiogenetic factors suggesting that CST-Post can be used as an anti-
maladaptive remodeling treatment.
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Introduction
The presence of comorbidities including hypertension and
myocardial hypertrophy has been reported to blunt the efficacy of
cardioprotective protocols such as ischemic postconditioning (I-
PostC) and to alter expression and responsiveness of several
kinases, including those involved in the so-called Reperfusion-
Injury-Salvage-Kinases (RISK)-pathway [1–4]. Although (RISK)-
pathway activation by I-PostC plays a causal role in cardioprotec-
tion in normal rodents, I-PostC effectiveness is compromised in the
hypertrophied hearts of spontaneously hypertensive rats (SHR)
[1,5,6]. Therefore there is a compelling need to find cardiopro-
tective strategies (e.g. pharmacological-PostC, P-PostC) [2,7] for
subjects affected by comorbidities.
Catestatin (CST:hCgA352–372), a 21-amino-acid derivate of
chromogranin A (CgA) [8–12] displays hypotensive/vasodilatory
properties and counteracts excessive systemic and/or intra-cardiac
excitatory stimuli (e.g., catecholamines and endothelin-1) [9–10].
Produced also by the myocardium [12], CST affects heart
performance by modulating inotropy, lusitropy and coronary tone
through a NO-dependent mechanism [8–10,13]. Notably, hyper-
tensive patients have lower CST levels than their normotensive
counterparts [11]. In fact, CST restores normal blood pressure in
CgA knockout mice, which represents monogenic-model of mouse
hypertension [11] CST also promotes angiogenesis/arteriogenesis
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and vasculogenesis in the unilateral mouse hind limb ischemia
model [14]. Recently it has been shown that CST activates a
PI3K/Akt/NOS-dependent pathway [8–10] and elicits cardio-
protection in healthy rodent hearts [15,16]. Importantly, this
CST-recruited anti-apoptotic PI3K/Akt/NOS dependent path-
way appears to elicit its PostC cardioprotective effects through a
mechanism, which also involves mitochondrial KATP channels and
redox-signaling [15,16]. Moreover, in non-ischemic hearts, CST
induces protein S-nitrosylation (SNO) [13], which is emerging as
an important reaction in relation to the cardioprotective redox
signaling [17–19] This information prompted us to test whether
CST can improve post-ischemic myocardial remodeling, in which
both anti-apoptotic and pro-angiogenetic processes play critical
role [20,21]. Specifically, we hypothesize that CST, given at the
early reperfusion, would trigger cardioprotective pathways,
including phosphorylation and SNO of critical cardiac proteins
in the cardiac hypertrophic model of SHR. Given the anti-
apoptotic and pro-angiogenetic properties of CST in normotensive
rats, we also hypothesize that CST would slow-down apoptosis
and augment the expression of the early pro-angiogenetic factor,
namely hypoxia-inducible factor-1 (HIF-1a) [22,23] in SHR, i.e.,
a polygenic-model of rodent hypertension [24] The involvement of
HIF-1a is of relevance, due to its central role in preconditioning
[22,23] and its redox sensitive expression [22].
Methods
Animals
Ethics Statement: the experiments were conducted in accor-
dance with the Directive 2010/63/EU of the European Parlia-
ment and were approved and supervised by the ethics committee
of the Department of Pharmacy, Health and Nutritional Sciences,
University of Calabria and by the ethics committee of the
University of Torino. All surgery was performed under anesthesia
and all efforts were made to minimize animal suffering.
Experiments were conducted in age-matched SHR and WKY
male rats (450–500 g; 6-month-old; Janvier, St Berthevin Cedex-
France). Animals were housed under controlled lighting and
temperature conditions with free access to standard rat chow and
tap water [24,25]. Blood pressure (BP) was measured daily by a
programmed electro-sphygmomanometer (BP-2000 series II;
Blood pressure analysis system. Visitech System) in order to
confirm the normotensive/hypertensive conditions of the animals
used in this study. BP measured before each experiment by tail-
cuff method was: WKY: Systolic BP= 12263 mmHg and
Diastolic BP=9062 mmHg; SHR: Systolic BP=18264 mmHg
and Diastolic BP= 14362 mmHg.
Isolated heart perfusion
Rats were anesthetized by i.p. of ethyl carbamate (2 g/kg rat)
[8,13], and hearts were rapidly excised, weighed and transferred in
ice-cold Krebs–Henseleit buffer solution (KHS) containing (in
millimoles) NaCl 113, KCl 4.7, NaHCO3 25, MgSO4 1.2, CaCl2
1.8, KH2PO4 1.2, glucose 11, mannitol 1.1, Na-pyruvate 5
(pH 7.4; 37uC; 95% O2/5% CO2) [9,15] for immediate aorta
cannulation. Retrograde perfusion was conducted at constant
flow-rate with KHS at 37uC. Heart weights were: WKY:
1,7560,18 g; SHR: 2,2560,2 g. Therefore the flow was adjusted
according to heart weight during stabilization to obtain a perfusion
pressure of 80–100 mmHg and kept constant (961 ml/min/g)
thereafter. To avoid fluid accumulation, the left ventricle (LV) was
pierced. A water-filled latex balloon, connected to a pressure
transducer (BLPR; WRI, Inc., Saratota, FL), was inserted through
the mitral valve into the LV, to allow cardiac mechanical
parameters recording. A second pressure transducer located above
the aorta recorded coronary pressure (CP). Inotropism was
evaluated in terms of left ventricular pressure (LVP; mmHg,
index of contractile activity), maximal value of the first LVP
derivative [+(LVdP/dT)max; in mmHg/sec, index of maximal LV
contraction rate] and end diastolic ventricular pressure (EDVP;
mmHg, index of contracture) [8,13,26]. LVP and CP were
recorded throughout the experiment using PowerLab data
acquisition system and analyzed using Chart software (ADInstru-
ments, Oxford-UK).
Experimental protocol (Fig. 1)
In hearts subjected to I/R protocols ischemia and reperfusion
were obtained just stopping and restarting the perfusion pump. In
order to analyze the damages and molecular effects induced by the
experimental maneuvers, after the 30 min ischemia, hearts were
subjected to either a period of 120-min of reperfusion (Long
reperfusion groups) or a period of 20-min of reperfusion only
(Short reperfusion groups).
Long reperfusion groups. In order to have a reference
group for the I/R and CST effects, hearts from normotensive
animals (WKY, n= 18) were harvested and allowed to stabilize for
40-min. After the stabilization period, hearts were divided in three
groups (WKY_Sham, WKY_I/R and WKY_CST-Post; Groups
1–3). In Group 1 (WKY_Sham, n= 6), hearts underwent
Figure 1. Experimental protocols. Before ischemia, hearts were
randomly allocated to 1 of the experimental groups. Sham groups
hearts were buffer perfused for a total of 90 or 190 minutes. The long
reperfusion experimental hearts underwent 40 minutes of stabilization,
30 minutes of ischemia, and 120 minutes of reperfusion. The short
reperfusion hearts underwent 40 minutes of stabilization, 30 minutes of
ischemia, and 20 minutes of reperfusion. CST-Post was infused during
the initial 20 minutes of reperfusion only, inhibitors were infused during
the final 5 minutes of stabilization, as indicated by the lines under the
bars, and during the initial 20 minutes of reperfusion.
doi:10.1371/journal.pone.0102536.g001
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additional 150-min perfusion only (total 190-min perfusion). In
Group 2 (n = 6) and Group 3 (n = 6) hearts were subjected to a
specific protocol, which consisted in 30-min of global no-flow
ischemia and a period of 120-min of reperfusion. In the
WKY_CST-Post (Group 3), CST (75 nM) was infused for 20-
min at the beginning of 120-min reperfusion [15,16].
After the stabilization period, hearts from hypertensive animals
were subjected to the same protocols. In particular, in Group 4
(SHR_Sham, n= 6), SHR hearts underwent 190-min perfusion
only. In Group 5 (SHR_I/R, n= 6), hearts were exposed to
30 min ischemia and then to 120-min reperfusion. In Group 6
(SHR_CST-Post; n = 6), CST (75 nM), was infused for 20-min at
the beginning of 120-min reperfusion [15,16].
In Groups 7 and 8, the action of CST-Post was studied in SHR
hearts in the presence of specific inhibitors of pivotal kinases in
cardioprotection, namely the PKC inhibitor, chelerythrine (CHE,
5 mM; SHR_CST-Post+CHE, Group 7, n= 6) [27], or the PI3K/
Akt inhibitor, Wortmannin (WN, 0.1 mM; SHR_CST-Post+WN,
Group 8, n= 6) [28]. The inhibitors were infused 5-min before
and 20-min after ischemia [16,28]. The inhibitors alone at these
concentrations do not affect I/R damages [27–30].
Short reperfusion groups. In Group 9, (WKY_Sham-short,
n = 6) SHR hearts underwent 90 min perfusion only. In Group 10,
WKY hearts (WKY_I/R-short, n = 6) were exposed to 30-min
ischemia and then to 20-min reperfusion only. In Group 11
(WKY_CST-Post-short, n = 6), hearts were perfused with CST
(75 nM) during the 20-min of reperfusion [15,16].
In Groups 12–14 (SHR_Sham-short, n = 6; SHR_I/R-short,
n = 6; SHR_CST-Post-short, n = 6), SHR hearts underwent
protocols similar to those of Groups 9–11.
Assessment at 120-min reperfusion
Infarct size. Infarct areas were assessed at the end of the 120-
min reperfusion as previously described [5,15–17,26–28] and the
necrotic mass was expressed as a percentage of total left ventricular
mass which was considered as risk area. Briefly, at the end of
reperfusion, each heart was removed from perfusion apparatus,
and the left ventricle (LV) was dissected into 2–3 mm circumfer-
ential slices. Following 20-min of incubation at 37uC in 0.1%
solution of nitro-blue-tetrazolium in phosphate buffer, unstained
necrotic tissue was carefully separated from stained viable tissue by
an independent observer. The weights of necrotic and non-
necrotic tissues were determined and the necrotic mass was
expressed as a percentage of risk area [5,15–17,26–28].
Apoptosis. Since in hypertrophic hearts apoptotic remodeling
is particularly important [31], we studied the level of apoptosis in
SHR hearts subjected to 30-ischemia and 120-min reperfusion
with and without CST, respectively. TUNEL staining was
performed according to the manufacturer (in situ Cell Death
Detection Kit, POD from Roche Diagnostics-Germany) [32].
Sections were rehydrated and incubated with proteinase K
(20 mg/mL) at 37uC for 20-min. They were washed twice with
PBS, and endogenous peroxidase was quenched with 0.3% H2O2
in PBS for 15-min. Slides were then rinsed and incubated with
TUNEL in a humidified box (37uC, 60-min); the reaction was
Figure 2. I/R Injury (infarct size and apoptosis) after 30-min ischemia and 120-min reperfusion. Infarct size (IS): the amount of necrotic
tissue is expressed as percentage of the left ventricle (% IS/LV), which is considered the risk area. Panel A: effects of CST-Post in normotensive (WKY)
or hypertensive (SHR) hearts. Panel B: effects of CST-Post in hypertensive (SHR) heart in the presence of antagonists. TUNEL analysis: the apoptotic
index of the cardiac muscle is in panel C. Tunel positive cardiomyocyte nuclei are shown by red arrows in panel D (WKY_Sham), panel E (SHR_Sham),
panel F (SHR_I/R), and panel G (SHR_CST-Post). Negative control (panel H) is obtained by using the same protocol without TdT enzyme.
Immunohistochemical localization of connexin 43 (green arrows) in the ventricular sections of SHR_Sham (panel I), SHR_I/R (panel L), and SHR_CST-
Post (panel M). **p,0.01, *p,0.05. Two way ANOVA, (n = 6 for each group).
doi:10.1371/journal.pone.0102536.g002
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blocked by 3% BSA in PBS at room temperature. Horseradish
peroxidase (HRP)-conjugated antibodies were added and incubat-
ed at 37uC. Negative controls were obtained by using the same
protocol without terminal deoxynucleotidyl transferase (TdT)
enzyme (Fig. 2 panel H). Nuclei were counterstained with
hematoxylin. Apoptotic Index (AI) was calculated as 1006(num-
ber of TUNEL-positive myocyte nuclei per field/total number of
myocyte nuclei per field). For each condition, four randomly
selected fields were evaluated and averaged [32].
Since cleaved caspase 3 and apoptosis repressor with caspase
recruitment domain (ARC) are highly involved in apoptosis
induced by I/R injury [33], the expression and localization of
ARC and cleaved caspase 3 was investigated in SHR ventricle of
both CST treated and untreated hearts. Cleaved caspase 3 and
Figure 3. Apoptotic factors after 30-min ischemia and 120-min reperfusion. Representative Western Blots and relative densitometry for
ARC (panel A) and for cleaved caspase 3 (panel B). Individual values were compared to b-actin and the mean value of the Sham group was considered
as the reference for all groups, including Sham. Immunohistochemical localization of the apoptosis repressor recruitment domain (ARC, white arrows)
in the ventricular cardiomyocytes of SHR Sham (D), SHR_I/R (E), SHR_CST-post (F) rat. Immunohistochemical localization of caspase 3 (blue arrows) of
WKY (G), SHR_Sham (H), SHR_I/R (I), SHR_CST-post (L) in the ventricular cells. (C) Negative control. *p,0.01. ANOVA followed by Bonferroni’s Multiple
comparison Test, (n = 6 for each group).
doi:10.1371/journal.pone.0102536.g003
Table 1. Pre and post ischemic cardiac function.
WKY SHR
Baseline
(Pre-isch)
I/R
(End rep)
CST-Post
(End rep)
Baseline
(Pre-isch)
I/R
(End rep)
CST-Post
(End rep)
dLVP (mmHg) 8564 4366** 84616 10664 57612** 135628
+(LVdP/dt)max (mmHg/sec) 27136132 17486103** 28576415 32906109 23216178* 39216718
EDVP (mmHg) 561 35611** 462 661 5967** 661
dLVP = developed left ventricular pressure (index of contractile activity); +(LVdP/dT)max =maximal value of the first LVP derivative (index of maximal LV contraction
rate); EDVP= end diastolic ventricular pressure (index of post-ischemic contracture); Pre-isch =before ischemia; End rep = at the end of reperfusion. Baseline value are
the pooled data of I/R and CST-Post groups. *p,0.05 vs. Baseline; **p,0.005 vs. Baseline.
doi:10.1371/journal.pone.0102536.t001
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ARC expression were analyzed by Western blotting (WB) on
ventricular homogenates as previously described [27,28,34].
Ventricular cleaved caspase 3 and ARC localization was
immune-histochemically evaluated by using a HRP/DAB detec-
tion kit (Abcam, Cambridge, MA-USA). Ventricular sections were
deparaffined, rehydrated in PBS and pre-treated with H2O2 to
remove endogenous peroxidase activity, incubated for 1-h with
Protein Block, and then overnight with polyclonal rabbit cleaved
caspase 3 (1:1000; Sigma-Aldrich St Louis, MO-USA) and ARC
antibodies (1:100; Santa Cruz Biotechnology) at 4uC. Slides were
then washed in PBS and incubated with Biotinylated goat anti-
rabbit IgG and subsequently with streptavidine peroxidase
complex. The signal was visualized by using diaminobenzidine
(DAB) as the final chromogen. Ventricular myocytes were
discriminated by polyclonal connexin 43 antibody (1:100; Santa
Cruz Biotechnology), by using the above described immunohis-
tochemical protocol.
HIF-1a. HIF-1a is involved in long-term cardioprotection
and its levels increase within 2-hours of reperfusion [22,35]. HIF-
1a mRNA levels were also evaluated by RT-PCR in 6 additional
samples collected after 2-hours reperfusion, for each experimental
condition. To evaluate gene expression, at the end of experiments
the left ventricles were excised, homogenized with a motor-driven
homogenizer and total RNA was isolated using the Trizol reagent
(Invitrogen, Milan-Italy), according to the manufacturer’s instruc-
tions. RNA integrity was confirmed by visualization of distinct
18S–28S bands after electrophoresis on 1.5% agarose gels stained
with ethidium bromide. To remove contaminating genomic DNA,
1 mg of RNA was treated with Rnase free Dnase (RQ1, Promega,
Qiagen, Milan-Italy) and then reverse transcribed using Moloney-
murine-leukaemia virus reverse transcriptase (MLV-RT; Invitro-
gen). As negative controls, duplicate RNA samples were incubated
in the same buffer with no MLV-RT. Two ml of cDNAs were used
for PCR using gene-specific primers. For HIF-1a, the PCR
conditions were 1-min at 94uC, 1-min at 56uC, and 1-min at 72uC
for 35 cycles using the following primers: forward, 59-
GCTGATTTGTGAACCCATTC-39 and reverse: 59-
CTGTACTGTCCTGTGGTGAC-39, generating a 155-bp prod-
uct. For glyceraldehyde-3-phosphate dehydrogenase, the PCR
conditions were 1-min at 94uC, 1-min at 58uC, and 1-min at 72uC
for 20 cycles using the following primers: forward, forward: 59-
ACCACAGTCCATGCCATCAC-39 and reverse: 59-TCCAC-
CACCCTGTTGCTGTA-39 generating a 452-bp product. PCR
products were analyzed on a 1% agarose gel and visualized by
ethidium bromide staining. Glyceraldehyde-3-phosphate dehydro-
genase (GPDH) was used as PCR amplification control [25].
Endothelial NOS (eNOS) Immunolocalization. Since
eNOS participates to CST-induced signaling and cardioprotection
Figure 4. Phospho-eNOS localization after 30-min ischemia and 120-min reperfusion. Immunolocalization of phospho-eNOS (B–G), in
SHR_Sham (B, C), SHR_I/R (D, E), SHR_CST-post (F, G) rat ventricular sections. The enzyme is localized mainly in vascular (yellow arrows) and
endocardial endothelium (red arrows). Negative control is shown in A. Nuclei are counterstained with Hoechst, (n = 3 for each group).
doi:10.1371/journal.pone.0102536.g004
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[9,10,13,36], we tested whether CST may affect eNOS activation
in post-ischemic hypertrophic hearts. Additional rat hearts
(SHR_Sham: n= 3; SHR_I/R n=3; SHR_CST-Post n= 3) were
flushed in PBS, fixed in methanol: acetone: water solution (2:2:1),
dehydrated in graded ethanol (90%–100%), cleared in xylol,
embedded in paraplast (Sigma-Aldrich), and serially sectioned at
8 mm. Sections were placed onto Superfrost Plus slides (Menzel-
Glaser, Braunschwerg-Germany), deparaffined in xylene, and
rehydrated in an alcohol gradient [37].
For immunodetection, sections were rinsed in TBS, incubated
with 1.5% BSA in TBS for 1-h, and incubated overnight at 4uC
with rabbit polyclonal antibody (1:100) directed against phospho-
eNOS (1:100; Santa Cruz Biotechnology). Signal was detected on
slides washed in TBS (3610-min), and incubated with FITC-
conjugated anti-rabbit IgG (1:100; Sigma-Aldrich). Nuclei were
counterstained with Hoechst (1:10.000; Sigma-Aldrich) for 5 min.
Slides were observed using a deconvolution microscope (DMI
4000 LEICA, Wetzlar-Germany) [37].
Hearts perfused with Krebs solution alone for 190 min (Sham
Group) were used to evaluate the basal level and stability of
studied enzyme throughout the experiment.
Assessment at 20 min reperfusion
WB for RISK pathway. Since RISK pathway is involved in
the CST induced signaling and cardioprotection in normotensive
hearts [16], we tested whether in hypertrophic hearts CST may
affect RISK pathway activation. Samples collected immediately
after the 20-min reperfusion were used in order to directly study
whether CST-Post is able to induce phosphorylation of Akt,
GSK3b, ERK1/2 and PKCe in early reperfusion. After stabili-
zation (40-min), rat hearts underwent 30-min global ischemia
followed by 20-min reperfusion (with and without CST). Hearts
perfused with KHS alone for 90-min (Sham-short Groups) were
used to evaluate the basal level and stability of phosphorylation of
kinases throughout the experiment. In brief, the supernatants
(60 mg proteins) [38] were subjected to SDS-PAGE on various
percent of acrylamide gels (8% for PKCe, phospho-PKCe; 10%
for Akt, phospho-Akt; GSK3b, phospho-GSK3b) and transferred
to PVDF membranes (GE Healthcare, Buckinghamshire-UK).
After blocking with non-fat dried milk (Santa Cruz Biotechnology)
membranes were then incubated overnight at 4uC with the
following primary antibodies: anti-Akt, anti-phospho-(Ser473)-Akt,
anti-GSK3b, (Cell Signaling Technology, Beverly, MA-USA),
anti-phospho-(Ser-9)-GSK3b, anti-PKCe, anti-phospho-(Ser729)-
PKCe, (Santa Cruz Biotechnology). To confirm equal protein
loading, membranes were incubated with an anti-b-actin antibody
(Sigma-Aldrich). Immunoblotted proteins were visualized using an
Immuno-Star HRP Substrate Kit (Bio-Rad Laboratories, Hercu-
les, CA-USA) and quantified by Kodak Image Station 440CF.
Image analyses were performed by Kodak 1D 3.5 software
Figure 5. HIF-a expression after 30-min ischemia and 120-min reperfusion. Representative RT-PCR (panel A) and Western Blots (panel B)
and relative densitometry for hypoxia-inducible factor-1a (HIF-1a). Individual values were compared to loading control and the mean value of the
Sham group was considered as the reference for all groups, including Sham. Immunohistochemical localization of HIF-1a in the ventricular sections of
SHR_Sham (D), SHR_I/R (E), SHR_CST-Post (F) rat. In E the inset shows a detail of HIF-1a labeled myocardiocytes. (C) Negative control. Blue arrows
(cardiomyocytes), red arrows (vascular endothelium). *p,0.01. ANOVA followed by Bonferroni’s Multiple comparison test, (n = 6 for each group).
doi:10.1371/journal.pone.0102536.g005
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[27,28]. Individual values (total and phosphorylated kinases) were
compared to b-actin and used to calculate the phospho/total ratio
of kinases. The mean value of the Sham group was considered as
the reference for all groups, including Sham.
Detection of SNO by Biotin switch assay (BS) and
WB. SNO of L-type calcium channels has been implicated in
cardioprotection [18,39]. Thus, we studied whether CST may
favor SNO of these channels in SHR and WKY hearts. To this
purpose BS assay was performed as described [13] on ventricular
homogenates collected during early reperfusion. Biotinylated
samples were separated on 10% SDS-PAGE gels, transferred to
membrane, blocked with non-fat dried milk and incubated with
streptavidin-peroxidase (Sigma-Aldrich) diluted 1:5000 for 1 h.
The membranes used for S-nitrosylation were stripped and re-
probed by using a polyclonal rabbit anti-L-type calcium channel
antibody (Santa Cruz Biotechnology). Immunodetection for both
WB and BS assay was performed with an enhanced chemilumi-
nescence kit (ECL-PLUS, GE-Healthcare, Buckinghamshire-UK).
Autoradiographs, obtained by exposure to X-ray films (Hyperfilm
ECL, GE-Healthcare), were digitalized and the densitometric
analysis of the bands was carried out using NIH IMAGE 1.6 for a
Macintosh computer based on 256 grey values (0 =white;
256= black) [13]. Individual values (total and nytrosylated
channel) were compared to b-actin and used to calculate the
nytrosylated/total ratio of protein channel. The mean value of the
Sham group was considered as the reference for all groups,
including Sham.
Drugs
Human CST was synthesized by the solid-phase method, using
9-fluorenylmethoxy-carbonyl protection chemistry [40]. Peptide
was purified to .95% homogeneity by preparative reverse-phase
HPLC on C-18 silica column. Authenticity and purity of peptide
was further verified by analytical chromatography (reverse-phase
HPLC) and electrospray-ionization or matrix-assisted laser
desorption mass spectrometry [40]. CHE, and WN were
purchased from Sigma-Aldrich.
Statistical analysis
All data are expressed as means6SEM. ANOVA followed by
Bonferroni’s Multiple comparison test and Newman–Keuls
multiple comparison test for post-ANOVA comparisons have
been used when appropriate. Two way ANOVA was used when
comparing WKY and SHR groups (Graphpad-Prism). A p value,
0.05 was considered statistically significant.
Figure 6. RISK pathway activation after 30 min ischemia and 20 min reperfusion. Western blot analysis for RISK pathway at 20-min of
reperfusion. Representative Western blots and relative densitometry showing that CST-Post given in early reperfusion results in an increased
phosphorylation of Akt, ERK1/2, PKCe and GSK3b with respect to I/R or Sham Group. Individual values were compared to b-actin and the mean value
of the Sham group was considered as the reference for all groups, including Sham. **p,0.01 vs. I/R_short,#p,0.05 vs. Sham_short. ANOVA followed
by Newman–Keuls multiple comparison test, (n = 6 for each group).
doi:10.1371/journal.pone.0102536.g006
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Results
CST-Post Limits I/R Injury (infarct size and apoptosis) after
30-min ischemia and 120-min reperfusion
In order to assess the effectiveness of CST-Post in limiting I/R
injury, infarct size and apoptotic indices were evaluated (Figs 2
and 3).
Infarct size (IS) is expressed as a percentage of risk area (Fig. 2,
panels A and B). We confirmed that CST was able to reduce IS in
WKY hearts and that, in the I/R group of SHR hearts, the IS was
larger (70611% of risk area) as compared to WKY group (Fig. 2,
panel A). We found significant reduction of IS (reduced to
2462%) in SHR_CST-Post (p,0.01 vs. SHR_I/R) (Fig. 2, panels
A and B).
The co-infusion with WN, an inhibitor of PI3K/Akt or CHE,
an inhibitor of PKC, blocked the protective effects of CST-Post in
SHR (IS was 5462% and 6262% respectively, p,0.05 vs.
SHR_CST-Post, and p=NS (not significant) vs. SHR_I/R for
both) (Fig. 2, panel B); similar results were observed for normal
hearts [16].
CST protective effects on I/R injury were confirmed by
assessing TUNEL-positive apoptotic cardiomyocytes. The apo-
ptotic index was similar in WKY and SHR_Sham, while I/R
increased the number of apoptotic cardiomyocytes in SHR_I/R
(p,0.05 vs. SHR_Sham). CST-Post was found to significantly (p,
0.05 vs. SHR_I/R) reduce the number of post-ischemic apoptotic
myocytes (Fig. 3, panel C). Apoptotic nuclei appear to be
condensed, fragmented and with dark stained nuclei (Fig. 2,
panels D–G). Cardiomyocytes were discriminated from other non-
myocyte cells by comparison with connexin 43 localization in
parallel ventricular sections (panels I–M).
Usually, it is recommended to employ two or more distinct
assays to confirm that cell death is occurring via apoptosis.
Therefore, to strength data on apoptosis we performed immuno-
blotting analysis (Fig. 3, panels A and B) and immunohistochem-
ical analysis (Fig. 3, panels D–L) of apoptosis repressor ARC and
cleaved caspase 3. We found a significant increase of ARC (panel
A) and a significant reduction of cleaved caspase 3 (panel B) in
SHR_CST-Post. ARC (panels D–F) and Caspase 3 (panels G–L)
immunohistochemical data confirmed immunoblotting densitom-
etry.
In immunohistochemical analysis, labeling specificity was
confirmed by the absence of the signal in parallel control sections
without the primary antibody (Fig. 3, panel C).
CST-Post improves post-ioschemic cardiac function
recovery
The data of I/R injury were corroborated by post-ischemic
cardiac function recovery (Table 1). CST limited the post-
ischemic myocardial contracture (EDVP) in both WKY and
SHR strain. Moreover CST improved post-ischemic contractile
activity (dLVP) and maximal LV contraction rate (dP/dtmax) in
both strains.
At the concentration used to dissolve WN, DMSO has not effect
on both I/R injury and post-ischemic cardiac function [28,41,42].
CST-Post enhances eNOS and HIF-a expression
To test whether CST-Post promotes early pro-angiogenic
factors, namely HIF-1a and eNOS we exposed rat ventricular
sections to phospho-eNOS and HIF-1a antibodies.
In SHR_Sham (Fig. 4, panels B, C) and SHR_I/R (Fig. 4,
panels D, E) the phospho-eNOS signal was localized at the level of
the ventricular endocardial-endothelium and to a lesser extent on
the vascular endothelium and on the myocardiocytes. After CST-
Post (Fig. 4, panels F, G) phospho-eNOS expression was strongly
increased in both coronary vessels and myocardiocytes.
Figure 7. S-nitrosylation of calcium channels after 30 min ischemia and 20 min reperfusion. Western blot analysis of S-nitrosylated
proteins in homogenized cardiac ventricles. S-nitrosylation of membrane protein fraction and stripped membrane incubated with an anti L-type
calcium channel antibody showing S-nitrosylation at the migration position corresponding to the L-type calcium channel in WKY (panel A) and SHR
(panel B) hearts. Individual values were compared to b-actin and the mean value of the Sham group was considered as the reference for all groups,
including Sham. *p,0.05 ANOVA followed by Newman–Keuls multiple comparison test, (n = 6 for each group).
doi:10.1371/journal.pone.0102536.g007
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Data on expression of HIF-1a were analyzed with RT-PCR and
Western Blotting analyses (Fig. 5, panels A and B). The levels of
HIF-1a mRNA and protein were significantly higher in I/R group
with respect to Sham. CST-Post leads to a further increase in the
expression of HIF-1a protein (panel B). Immunohistochemical
analyses revealed the presence of HIF-1a in ventricular cardio-
myocytes. Augmented expression of HIF-1a was seen particularly
in coronary vessel endothelium in I/R (panel E) as compared to
Sham groups (panel D). CST-Post treatment, HIF-1a expression
was found to have increased further in both cardiomyocytes and
coronaries (panel F).
Similar results were obtained in parallel experiments performed
on WKY_I/R and WKY_CST-Post groups (data not shown).
In both immunofluorescence and immunohistochemical analy-
ses, labeling specificity was confirmed by the absence of the signal
in parallel control sections without the primary antibody (Figs 4A,
5C).
CST triggers RISK pathway and SNO of calcium channel in
SHR hearts after 30-min ischemia and 20-min reperfusion
(Figs 6 and 7)
In order to evaluate posttranslational protein modifications
induced by CST-Post, we analyzed the phosphorylation of critical
proteins of the RISK pathway (Fig. 6) and the S-nitrosylation of an
important component of calcium handling (Fig. 7). The represen-
tative bands and densitometric analysis of the scanned blots
detected at the 20th-min of reperfusion in SHR hearts are
presented in Fig. 6. Data are normalized with respect to the mean
value of single value loading of b-actin. The infusion of CST-Post
enhanced phosphorylation of all kinases analyzed. In particular, it
induced a marked activation/phosphorilation of Erk1/2, PKCe
and Akt with respect to I/R group. In addition, CST infusion
caused increased phosphorylation/inhibition of GSK3b, which
represents the putative end-effector of RISK pathway. Similar
results were obtained in parallel experiments performed on
WKY_I/R and WKY_CST-Post groups (data not shown).
L-type calcium channel S-nitrosylation (Fig7). While I/R
induced a significant decrease of S-nitrosylation of L-type calcium
channels in SHR strain, CST-Post increased the S-nitrosylation of
calcium channels in both WKY and SHR hearts as determined by
Biotin switch method in combination with Western blot (Fig. 7,
panels A and B).
Discussion
The present study indicates that CST when given in the early
reperfusion in the hypertrophic heart of SHR 1) reduces infarct
size, 2) limits apoptosis, and 3) increases the expression of pro-
angiogenetic factors, namely HIF-1a and eNOS, already two-
hours after the beginning of perfusion. These effects are
accompanied by the activation of the RISK pathway and calcium
channel S-nitrosylation. Taken together, these results in CST-Post
group strongly support a cardioprotective/proangiogenetic role of
the peptide.
Several studies revealed that the effectiveness of cardioprotec-
tive protocols (e.g., ischemic preconditioning and postcondition-
ing) is blunted in the presence of comorbidities, such as diabetes,
hypercholesterolemia, hyperglycemia, obesity or hypertension
[1,5,6]. As shown in different models of cardiac hypertrophy, this
higher ischemic susceptibility is attributed to altered levels of
kinases phosphorylation [43–45] and an increased cell loss by
apoptosis and necrosis [46]. Consistent with this point, we recently
demonstrated a reduced I-PostC protection against infarct
development in hypertrophic SHR hearts [5]. Accordingly,
greater attention has been paid to understand the mechanisms
underlying the protection of the diseased heart.
Here we report for the first time that in the SHR model the
CST treatment immediately after ischemia, namely P-PostC,
induced the same cardioprotective profile as ischemic pre- and
post-conditioning in normotensive animals, i.e. CST activated
PI3K/Akt, PKCe and ERK1/2, which may converge on GSK-
3b, a substrate of multiple pro-survival protein kinases. Indeed,
GSK-3b phosphorylation/inactivation is considered a point of
convergence for multiple protective signaling pathways [15,16,47].
Our findings that inhibitors of PI3K/Akt and PKC blunt the
CST-Post protection suggest that, also in SHR, the infarct-limiting
effect of CST-Post is mechanistically linked to RISK-dependent
activation. It is likely that CST reaches the threshold for eliciting
cardioprotection with pharmacological PostC in SHR. Moreover,
this is also the first report that CST-induced SNO of calcium
channels is observed in post-ischemic phase. Of note, this
posttranslational modification of a L-type calcium channel subunit
has already been described in preconditioning cardioprotection by
Murphy et al. [18,39] and in non-ischemic hearts treated with
CST by Angelone et al. [13]. CST-induced NOS activation [8,9]
and bioactive NO-dependent S-nitrosylation [13] are important
effectors of the peptide cardio-activity. The CST-Post-elicited S-
nitrosylation of L-type calcium channel may be functionally
important. Notably CST can reverse the S-nitrosylation down-
regulation induced by I/R in SHR. The striking improvement of
post-ischemic cardiac function induced by CST-Post (Table 1)
might be correlated with calcium channel S-nitrosylation. In fact,
due to calcium overload post-ischemic heart develops an intense
contracture which compromise contractile function. The S-
nitrosylation of L-type calcium channel may limit calcium
overload and may allow a better functional recovery of surviving
cardiomyocytes [18,39]. This aspect deserves future studies.
Since acute post-ischemic apoptosis followed by maladaptive
remodeling are particularly evident in hypertrophic hearts, such as
SHR heart [31], attempts have been made to develop therapeutic
strategies to protect the heart against early I/R damages by
reducing the onset of apoptosis and subsequent maladaptive
remodeling. Therefore, we analyzed whether in SHR hearts CST-
dependent protection positively modulated post-infarction cardiac
repair by limiting apoptosis and triggering adaptive processes. We
found that the early infusion of CST in SHR post-ischemic hearts
significantly reduced apoptosis (less TUNEL-positive nuclei and
cleaved caspase), concomitant with an increased ARC-expression.
Remarkably, ARC is a master regulator of cell death, by inhibiting
apoptosis mediated by both the death-receptor and mitochondrial
pathways [31]. In the SHR model, ARC is significantly lower in
cardiac tissue (our study), as well as in skeletal, and smooth muscle
[31], whereas in the heart of normal animals ARC over-expression
inhibits caspase-8 activation by blocking the formation of death-
inducing signaling complex [33,48].
In the context of the hypoxic stress scenario, it is of interest that
we found significantly increased levels of pro-angiogenetic HIF-1a
in SHR exposed to CST-Post with respect to I/R Group. It is
known that in normal hearts HIF-1a is a key mediator of ischemic
pre- and post-conditioning and its increase is detected in post-
ischemic hearts few hours after the induction of the cardioprotec-
tive strategies [23,49]. It crucially contributes to cell survival
during hypoxic stress, as that occurring during ischemia
[22,23,49]. This effect is obtained via activation of several critical
genes [31], including NOS [36]. Consistent with this HIF-1a/
eNOS interaction, we found in CST-treated SHR hearts a parallel
increase in HIF-1a and eNOS expression. Therefore, it is
conceivable that the induction of a CST-dependent rapid
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stabilization of HIF-1a under post-ischemic conditions could
contribute to extend the temporal range of the cardioprotective
influence of this peptide.
Translational implications
Recent evidence indicates that in both the normal and SHR
hearts the full-length CgA is present and proteolytically processed
to several derived peptides, such as the cardioactive and
cardioprotective VS-1 [50] and CST [12]. Although the spatio-
temporal aspects of the CgA intracardiac processing remain to be
studied in depth, it is possible that, like VS-1, also CST can
orchestrate its cardio-activity in an autocrine and paracrine
manner. Current myocardial preservation strategies may be
inadequate at protecting the myocardium from the acute I/R
injury which occurs either on post-acute myocardial infarct (AMI)
or on aortic cross-clamping and -declamping during on-pump
coronary artery bypass graft surgery, especially in the presence of
comorbidities [1]. Therefore, novel therapeutic strategies, such as
P-PostC, are required to protect the heart against I/R injury and
reduce the extent of damage in high-risk patients undergoing post-
AMI reperfusion procedures or aortic cross-declamping, to
preserve ventricular systolic function and improve clinical
outcomes. It is possible that the lack of CST in hypertensive
conditions may be responsible of the exacerbation of I/R injury.
We suggest, that an early pharmacological regime with CST (i.e.
CST-Post) may be necessary to limit reperfusion injury, especially
in conditions in which the peptide is lacking.
In conclusion, we show that CST, given in the early reperfusion,
reduces infarct size and improves cardiac function in the post-
ischemic SHR hearts, activates the RISK-pathway, elicits calcium
channel S-nitrosylation in early reperfusion, while increasing two-
hours after the beginning of reperfusion the expression of anti-
apoptotic and pro-angiogenic factors, i.e. ARC, HIF-1a and
eNOS. Taken together, the data support CST as a potential
modulator in the post-ischemic scenario and a therapeutic agent
for protecting the heart against I/R injury despite the presence of
comorbidities such as hypertension and cardiac hypertrophy.
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